drugset / Trial / NCT00857948

Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation

NCT00857948

Phase 2 Completed 78 enrolled Topaz Pharmaceuticals Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 2 single center study designed to compare the safety, local tolerability, and efficacy of 3 strengths of ivermectin treatment conditioner to placebo.

Timeline

Start
2009-03
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivermectin Small molecule 0.15 % Topical
Subject Ivermectin Small molecule 0.25 % Topical
Subject Ivermectin Small molecule 0.5 % Topical